KScan and HCC
Research type
Research Study
Full title
Developing a KScan diagnostic for patient stratification of first line systemic hepatocellular carcinoma therapies
IRAS ID
330380
Contact name
Debashis Sarker
Contact email
Sponsor organisation
Kinomica Ltd
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
Primary liver cancer is the fourth most prevalent cancer worldwide and is predicted to cause 1 million deaths by 2030 [WHO/UN data]. Hepatocellular Carcinoma (HCC) accounts for 90% of all liver cancer cases with around 5,900 new cases in the UK every year, and incidence is projected to rise by 38% by 2035 [CRUK]. Overall survival remains poor at <20% at 5 years. However, systemic therapy options for these patients is increasing, and includes immunotherapies as well as targeted therapies. Consequently, all HCC patients are currently required to have baseline biopsies taken, as part of standard clinical care, prior to starting systemic therapies, with the intention of providing individualised care where possible. The aim of the proposed work is to extract the biological signature (phosphoproteomics) of a given patient's cancer from tumour tissue that is obtained during standard of care surgery or biopsy procedures. This data will then be computationally modelled to develop an algorithm to identify features in the biological signature that can be used to
predict whether the patient will respond to one therapy over another.REC name
South Central - Hampshire A Research Ethics Committee
REC reference
23/SC/0329
Date of REC Opinion
24 Sep 2023
REC opinion
Favourable Opinion